ARTICLE
19 March 2021

Federal Circuit Affirms PTAB's Rejection Of Patent Application As Abstract

FH
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Contributor

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is a law firm dedicated to advancing ideas, discoveries, and innovations that drive businesses around the world. From offices in the United States, Europe, and Asia, Finnegan works with leading innovators to protect, advocate, and leverage their most important intellectual property (IP) assets.
In In re Bd. of Trs. of the Leland Stanford Junior Univ., No. 2020-1012 (Fed. Cir. Mar. 11, 2021), the Federal Circuit affirmed the PTAB's rejection of a patent application under 35 U.S.C. § 101...
United States Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

In  In re Bd. of Trs. of the Leland Stanford Junior Univ., No. 2020-1012 (Fed. Cir. Mar. 11, 2021), the Federal Circuit affirmed the PTAB's rejection of a patent application under 35 U.S.C. § 101, holding that it claimed a patent-ineligible mental process combined with mathematical algorithms.

The application claims a method for resolving haplotype phase for determining the parents from which genes are inherited. The USPTO rejected the claims, finding that the recited steps of "receiving" data and "determining," "storing," and "providing" information constituted a mental process that could be performed within the human mind, together with mathematical algorithms. The first claim also recited a "computer system comprising a processor and a memory" in each step of the method. The USPTO noted that the claims recited only generic computer components insufficient to make the claims patent eligible. On appeal, the PTAB affirmed.

The Federal Circuit affirmed, stating the claims were merely a mathematical algorithm and did not provide a concrete application for the haplotype data. The Federal Circuit noted the absence of a specialized computer or components and held that an improvement in the process of resolving haplotype phase does not "transform[] the claims into a patent eligible application."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More